Showing results (1-10 of 418) with videos related to
Sort By:
Pageof 42
Journal of Geriatric Oncology|May 24, 2011
Phase I Clinical Trials in Patients ≥80Himabindu Gaddipati, Pingfu Fu, Afshin DowlatiJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survivalPingfu Fu, Afshin Dowlati, Mark SchluchterClinical Lung Cancer|February 4, 2014
Clinical trial design in small cell lung cancer: surrogate end points and statistical evolutionMyles Nickolich, Shahab Babakoohi, Pingfu Fu, et al.Cancer Research Communications|December 3, 2025
Roles of restricted mean survival time and restricted mean time lost in evaluating immune checkpoint inhibitor efficacy for extensive-stage small cell lung cancerSeren Durer, Pingfu Fu, Zhengyi Chen, et al.Investigational New Drugs|October 9, 2016
Evaluating the role of phase I expansion cohorts in oncologic drug developmentRobin E Norris, Mohadese Behtaj, Pingfu Fu, et al.Investigational New Drugs|December 10, 2009
Temporal evolution of patient characteristics enrolled on phase I trialsAfshin Dowlati, Madappa Kundranda, Sudhir Manda, et al.Reviews on Recent Clinical Trials|September 17, 2016
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung CancerPingfu Fu, Nathan A Pennell, Neelesh Sharma, et al.Clinical Lung Cancer|September 27, 2012
Combined SCLC clinical and pathologic characteristicsShahab Babakoohi, Pingfu Fu, Michael Yang, et al.Translational Lung Cancer Research|March 25, 2020
A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancerMichelle Chiu, Mary Beth Lipka, Priyanka Bhateja, et al.Lung Cancer (Amsterdam, Netherlands)|December 13, 2006
Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancerTania Cortas, Rosana Eisenberg, Pingfu Fu, et al.Pageof 42